By Feroz Jameel, Susan Hershenson
A real-world advisor to the construction and production of biopharmaceuticals
While a lot has been written concerning the technological know-how of biopharmaceuticals, there's a want for useful, updated details on key concerns in any respect phases of constructing and production commercially conceivable biopharmaceutical drug items. This e-book is helping fill the distance within the box, studying all parts of biopharmaceuticals production, from improvement and formula to creation and packaging.
Written through a bunch of specialists from and academia, the e-book makes a speciality of real-world tools for holding product integrity during the commercialization method, essentially explaining the basics and crucial pathways for all improvement levels. assurance comprises:
Research and early improvement phase?appropriate ways for making sure product stability
Development of commercially plausible formulations for liquid and lyophilized dosage forms
Optimal garage, packaging, and transport methods
Case reports with regards to healing monoclonal antibodies, recombinant proteins, and plasma fractions
Useful research of profitable and failed products
Formulation and procedure improvement recommendations for production Biopharma-ceuticals is an important source for scientists and engineers within the pharmaceutical and biotech industries, for presidency and regulatory corporations, and for someone with an curiosity within the most modern advancements within the field.Content:
Chapter 1 The constitution of organic Therapeutics (pages 1–40): Sheryl Martin?Moe, Tim Osslund, Y. John Wang, Tahir Mahmood, Rohini Deshpande and Susan Hershenson
Chapter 2 Chemical Instability in Peptide and Protein prescribed drugs (pages 41–67): Elizabeth M. Topp, Lei Zhang, Hong Zhao, Robert W. Payne, Gabriel J. Evans and Mark Cornell Manning
Chapter three actual balance of Protein prescription drugs (pages 69–104): Byeong S. Chang and Bernice Yeung
Chapter four Immunogenicity of healing Proteins (pages 105–117): Steven J. Swanson
Chapter five Preformulation learn: Assessing Protein resolution habit in the course of Early improvement (pages 119–146): Bernardo Perez?Ramirez, Nicholas Guziewicz and Robert Simler
Chapter 6 formula improvement of part 1–2 Biopharmaceuticals: a good and well timed procedure (pages 147–159): Nicholas W. Warne
Chapter 7 Late?Stage formula improvement and Characterization of Biopharmaceuticals (pages 161–171): Adeola O. Grillo
Chapter eight An Empirical part Diagram–High?Throughput Screening method of the Characterization and formula of Biopharmaceuticals (pages 173–205): Sangeeta B. Joshi, Akhilesh Bhambhani, Yuhong Zeng and C. Russell Middaugh
Chapter nine Fluorescence and Phosphorescence the way to Probe Protein constitution and balance in Ice: The Case of Azurin (pages 207–229): Giovanni B. Strambini
Chapter 10 functions of Sedimentation speed Analytical Ultracentrifugation (pages 231–251): Tom Laue
Chapter eleven box circulation Fractionation with Multiangle gentle Scattering for Measuring Particle measurement Distributions of Virus?Like debris (pages 253–268): Joyce A. Sweeney and Christopher Hamm
Chapter 12 Light?Scattering options and their program to formula and Aggregation issues (pages 269–305): Michael Larkin and Philip Wyatt
Chapter thirteen potent methods to formula improvement of Biopharmaceuticals (pages 307–328): Rajiv Nayar and Mitra Mosharraf
Chapter 14 Prediction of Aggregation Propensity from basic series info (pages 329–347): Mark Cornell Manning, Gabriel J. Evans, Cody M. Van Pelt and Robert W. Payne
Chapter 15 High?Concentration Antibody Formulations (pages 349–381): Steven J. Shire, Jun Liu, Wolfgang Friess, Susanne Jorg and Hanns?Christian Mahler
Chapter sixteen improvement of Formulations for healing Monoclonal Antibodies and Fc Fusion Proteins (pages 383–427): Sampathkumar Krishnan, Monica M. Pallitto and Margaret S. Ricci
Chapter 17 Reversible Self?Association of Pharmaceutical Proteins: Characterization and Case experiences (pages 429–455): Vikas okay. Sharma, Harminder Bajaj and Devendra S. Kalonia
Chapter 18 layout of a formula for Freeze Drying (pages 457–492): Feroz Jameel and Mike J. Pikal
Chapter 19 Protein Conformation and Reactivity in Amorphous Solids (pages 493–506): Lei Zhang, Sandipan Sinha and Elizabeth M. Topp
Chapter 20 The influence of Buffer on Solid?State houses and balance of Freeze?Dried Dosage kinds (pages 507–519): Evgenyi Y. Shalaev and Larry A. Gatlin
Chapter 21 Stabilization of Lyophilized prescription drugs via keep watch over of Molecular Mobility: impression of Thermal historical past (pages 521–548): Suman Luthra and Michael J. Pikal
Chapter 22 Structural research of Proteins in Dried Matrices (pages 549–563): Andrea Hawe, Sandipan Sinha, Wolfgang Friess and Wim Jiskoot
Chapter 23 The effect of formula and Drying techniques at the features and function of Biopharmaceutical Powders (pages 565–585): Vu L. Truong and Ahmad M. Abdul?Fattah
Chapter 24 production basics for Biopharmaceuticals (pages 587–604): Maninder Hora
Chapter 25 Protein balance in the course of Bioprocessing (pages 605–624): Mark Cornell Manning, Gabriel J. Evans and Robert W. Payne
Chapter 26 Freezing and Thawing of Protein recommendations (pages 625–675): Satish ok. Singh and Sandeep Nema
Chapter 27 options for Bulk garage and cargo of Proteins (pages 677–704): Feroz Jameel, Chakradhar Padala and Theodore W. Randolph
Chapter 28 Drying strategy equipment for Biopharmaceutical items: an summary (pages 705–738): Ahmad M. Abdul?Fattah and Vu L. Truong
Chapter 29 Spray Drying of Biopharmaceuticals and Vaccines (pages 739–761): Jim Searles and Govindan Mohan
Chapter 30 improvement and Optimization of the Freeze?Drying strategies (pages 763–796): Feroz Jameel and Jim Searles
Chapter 31 concerns for profitable Lyophilization technique Scale?Up, expertise move, and regimen creation (pages 797–826): Samir U. Sane and Chung C. Hsu
Chapter 32 technique Robustness in Freeze Drying of Biopharmaceuticals (pages 827–837): D. Q. Wang, D. MacLean and X. Ma
Chapter 33 Filling methods and applied sciences for Liquid Biopharmaceuticals (pages 839–856): Ananth Sethuraman, Xiaogang Pan, Bhavya Mehta and Vinay Radhakrishnan
Chapter 34 Leachables and Extractables (pages 857–880): Jim Castner, Pedro Benites and Michael Bresnick
Chapter 35 basic box and Closure choice for Biopharmaceuticals (pages 881–896): Olivia Henderson
Chapter 36 Prefilled Syringes for Biopharmaceuticals (pages 897–916): Robert Swift
Chapter 37 influence of producing techniques on Drug Product balance and caliber (pages 917–940): Nitin Rathore, Rahul S. Rajan and Erwin Freund
Read or Download Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals PDF
Similar manufacturing books
Lean pondering is a strong process that permits corporations to enhance the productiveness, potency, and caliber in their product or service. attaining those merits calls for strong teamwork, transparent conversation, clever use of assets, and a dedication to non-stop development. This e-book indicates how lean considering may be utilized in perform, highlighting the most important demanding situations and pitfalls.
"Mass tort litigation opposed to the gun undefined, with its useful weaknesses, successes, and ambitions, offers the framework for this number of considerate essays by means of top social scientists, legal professionals, and teachers. . . . those proficient analyses display the complexities that make the talk so tough to unravel.
International worth chains are noticeably changing how items and prone are produced. components made in a single state, for example, are more and more assembled in one other and bought in a 3rd. The globalisation of construction has replaced the economic constitution inside OECD international locations, and in a few sectors blunted their competitiveness.
That allows you to compete in an more and more difficult industry, many production businesses need to remodel or restructure their production structures in order that a suite of coherent production ideas may be supported. So this e-book goals to supply a entire therapy of producing method research (MSA) and production structures layout (MSD).
- Advances in Sustainable Manufacturing: Proceedings of the 8th Global Conference on Sustainable Manufacturing
- Performance evaluation of industrial systems : discrete event simulation in using Excel/VBA
- Tool and Manufacturing Engineers Handbook, Vol 1 : Machining
- Textile Fibers, Dyes, Finishes and Processes: A Concise Guide
- New Product Development and Delivery: Ensuring Successful Products Through Integrated Process Management
- Manufacturing Strategy: The Research Agenda for the Next Decade Proceedings of the Joint industry University Conference on Manufacturing Strategy Held in Ann Arbor, Michigan on January 8–9, 1990
Extra resources for Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals
B. and Kaarsholm, N. C. (2000), Structural effects of protein lipidation as revealed by LysB29-myristoyl, des(B30) insulin, Biochemistry 39: 11893–11900. 31. , and Shen, W. C. (2005), Reversible lipidization prolongs the pharmacological effect, plasma duration, and liver retention of octreotide, Pharm. Res. 22: 220–227. 32. Moore, W. V. and Leppert, P. (1980), Role of aggregated human growth hormone (hGH) in development of antibodies to hGH, J. Clin. Endocrinol. Metab. 51: 691–697. 33. , Gajdusek, D.
Purified imiglucerase is a monomeric glycoprotein of 497 amino acids, containing four N -linked glycosylation sites and has a molecular weight of 60,430 Da. Imiglucerase differs from placental glucocerebrosidase by one amino acid at position 495, where histidine is substituted for arginine. Somewhat different from the carbohydrate structures of native placental glucocerebrosidase, the oligosaccharide chains have been modified to terminate in mannose sugars. These mannose-terminated oligosaccharide chains are specifically recognized by endocytic carbohydrate receptors on macrophages, the cells that accumulate lipid in Gaucher’s disease.
Broadly, IgG1 and IgG3 are more competent at inducing cytotoxicity than are IgG2 and IgG4 [18,90]. If the mechanism of drug action requires a cytotoxic event, then IgG1 may be the most desirable subclass with the best half-life. If effector function is not needed or is considered undesirable then IgG2 or IgG4 may be preferred. For example, denosumab, recently filed for postmenopausal osteoporosis and patients 24 THE STRUCTURE OF BIOLOGICAL THERAPEUTICS undergoing hormone ablation for prostate or breast cancer, is an IgG2, which may provide a safety advantage (Amgen, filed in 2008) [91–93].